License Agreement (Details Textual) - USD ($) $ in Thousands |
1 Months Ended | 11 Months Ended | 12 Months Ended | |
|---|---|---|---|---|
Jun. 17, 2015 |
Dec. 31, 2015 |
Dec. 31, 2017 |
Dec. 31, 2016 |
|
| Payments to Acquire in Process Research and Development | $ 3,000 | $ 0 | $ 0 | |
| IV Tramadol [Member] | Fortress Biotech, Inc [Member] | ||||
| Payments to Acquire in Process Research and Development | $ 3,000 | |||
| Contractual Obligation, Maximum Future Payments | 4,000 | |||
| IV Tramadol [Member] | Fortress Biotech, Inc [Member] | Upfront Payment [Member] | ||||
| Payments to Acquire in Process Research and Development | 2,000 | |||
| IV Tramadol [Member] | Fortress Biotech, Inc [Member] | Additional Payment [Member] | ||||
| Payments to Acquire in Process Research and Development | $ 1,000 | |||
| X | ||||||||||
- Definition Amount of required maximum future payments under contractual obligation. No definition available.
|
| X | ||||||||||
- Definition The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|